Patients with confirmed multiple sclerosis (MS), with worse prognosis given the higher disease activity, in productive age between 18 and 60 years, with EDSS<5, who at the time of investigation are on baseline therapy of the disease for at least 3 months
Conditions
Brief summary
Primary endpoint: Annualized change in brain volume and gray matter volume. Serum neurofilament L level.
Detailed description
Secondary end points: Insulin sensitivity through ISI Cederholm, ISI Matsuda, HOMA-IR and HOMA-IR2. Scores in Symbol Digit Modalities Test (SDMT) and Stroop Test.
Interventions
Sponsors
Comenius University Bratislava
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary endpoint: Annualized change in brain volume and gray matter volume. Serum neurofilament L level. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end points: Insulin sensitivity through ISI Cederholm, ISI Matsuda, HOMA-IR and HOMA-IR2. Scores in Symbol Digit Modalities Test (SDMT) and Stroop Test. | — |
Countries
Slovakia
Outcome results
None listed